Ductal carcinoma-in-situ (or DCIS) was an uncommon entity before the introduction of mammographic screening (<5% of clinically detected lesions) but a common finding since its introduction (~20-30% mammographically detected lesions) (22).Paradoxically, while invasive Stage I and II breast cancers are now treated with breast conserving surgery and post-operative radiotherapy, the non-invasive malignant lesion (DCIS) historically has been treated with mastectomy. Although these results have been excellent(23), the desire to also treat this condition with smaller resections has led to some centres attempting more conservative approaches such as observation or radiotherapy after lumpectomy.Pathologists have demonstrated in mastectomy specimens that DCIS is often described as multicentric (32%[22] -76%[24[), with multicentricity and focal invasion related to lesion size (>25mm)(22). Holland(25) however favoured sampling of a three dimensional DCIS "tree" as the explanation for multicentricity, finding only 1 of 82 cases with non-contiguous spread. More meticulous examination of operative specimens has led to the understanding that DCIS lesions are often larger than appreciated on mammogram or clinical examination.Histological subtype (comedo v non-comedo) has prognostic significance. Comedo DCIS is of a higher nuclear grade, more likely to be associated with microcalcification and microinvasion.(25) Fortunately nodal involvement in DCIS is rare; positive axillary lymph nodes probably reflect sampling error in the pathology.Previous experience in lumpectomy for DCIS has been gained in only small numbers of patients. Lagios treated 79 patients with histologically completely excised large DCIS lesions (>25mm) prospectively with local excision alone. At 5.7 years (median follow up) 10 patients (13%) had recurred, with half (6.5%) being invasive lesions. (26)Radiotherapy experience for DCIS is similarly small. Of 67 patients with DCIS treated at the Institut Curie, 7 (%4.7) recurred at 5 years, with 5 being invasive recurrences.(23)This report(27) from the National Surgical Adjuvant Breast and Bowel Project, known as NSABP-B17, describes the initial results of a trial comparing observation with adjuvant radiotherapy in a group of patients treated with lumpectomy.
Trial Summary
Fisher et al.27 report a collaborative multi-institutional, prospective, randomised clinical trial comparing lumpectomy followed by observation with lumpectomy followed by radiotherapy after complete surgical excision of DCIS.The trial accrued 818 patients between October 1, 1985 and December 31, 1990 . The study found a statistically significant reduction in 'event-free survival' (EFS) after complete excision followed by radiotherapy. This reduction was seen entirely in ipsilateral breast cancers, and most markedly in invasive ipsilateral cancers. There were no patient deaths from breast cancer.
Trial Design Hypothesis
The proposed null hypothesis states that in women with completely excised DCIS, "adjuvant breast irradiation adds no advantage in terms of ipsilateral second malignancy rates".
Sample size and Statistical Power
The ability of a study to demonstrate a significant difference depends on both the magnitude of the real difference and the size of the sample studied. Small real differences can only be reliably demonstrated in large samples. The previous reliance on p values has been discouraged in favour of both confidence intervals, as a more accurate guide to significance(4), and the power of the intended study.The power of a study should be estimated prospectively (i.e., before the study begins accrual) based on the likely difference between the study arms. Usually the outcome in the "control" arm reflects that obtained by standard treatment and is previously quantified. The treatment arm outcome may be previously quantified (retrospective studies) or estimated by clinical relevance (e.g., "a decrease in disease recurrence at 5 years of 50%")(5,28).Neither the predetermined sample size nor the power of the study were described in this study. However, using the tables based on the method of Casagrande et al (29) ., a randomised trial with 381 patients per arm would have 80% one-sided power at the p=0.05 level, where the lower failure rate is 5%, and is 5% lower than the other arm (i.e., has a 10% failure rate). This trial, with historical outcomes of 13% 5-year recurrence post-lumpectomy(22), 5% 5-year recurrence post-lumpectomy and adjuvant radiotherapy(23), and 818 accrued patients exceeds these criteria. This study has the power to detect the expected pre-trial differences.
Trial Conduct

Eligible Population
Eligibility criteria listed were adequate to ensure that the sample of women included had DCIS, a pathological diagnosis and adequate surgery performed before inclusion. The matter of pathological review will be discussed later.
Patient Selection
The trial includes a wide range of DCIS patients. In the past there have been reports of adverse prognostic clinical features, such a presentations of Paget's disease of the nipple, nipple discharge, large palpable lesions (22, 23, 26) which are not controlled by stratification (see below). A large number of patients had very small DCIS lesions (~43% were <1mm) of uncertain prognosis.The management of multicentricity is also not addressed, although the validity of this diagnostic category has been addressed by Holland et al.(25) 16 patients were inappropriately included but nevertheless analysed.30Patient StratificationPatient stratification at randomisation is a method that controls the balance of known prognostic variables, and is particularly useful when an imbalance of prognostic factors would render analysis meaningless, and where combinations of prognostic factors may delineate at risk subsets. In this trial patients were stratified at randomisation for :
• age (49 and >49)
• axillary dissection (performed or not performed)
• tumour type (DCIS and DCIS/LCIS) • method of detection (clinical and mammography)However other prognostic factors of known importance were not included, but appear to be evenly distributed :histopathological subtype (comedo and non-comedo) • tumour size (<25mm and >25mm)
• clinical syndrome. (Paget's, nipple discharge) Failure to include histological subtype (comedo/non-comedo) and tumour size as stratification factors is a glaring deficiency since these factors have prognostic significance. Any future subgroup analysis will therefore be suspect.
Patient Randomisation
The method was adequately referenced, and reliable.
Patient Exclusion
There were two groups of patients excluded. 24 patients from a Montreal institution were excluded as the result of a NSABP decision after irregularities in the procedures of one surgeon31. Only 4 patients were excluded for inadequate follow-up.T
reatment Description Surgery
The 'gold standard' of therapy of mastectomy has not been compared by randomised prospective trial to lumpectomy alone or with adjuvant radiotherapy. Retrospective and prospective data has shown an increased rate of ipsilateral breast cancer recurrence with less than mastectomy (23, 26, 32) . Given this lack of data, a trial arm treated with mastectomy should have been included to permit a comparison of overall survival rates.The method of complete excision is incompletely described, omitting specimen processing. Specimen orientation with radiography is now considered good surgical practice. The method of "lumpectomy" is not described here33, Some investigators have described complete excision as a variable procedure.(34)The process described in the report is inadequate to permit a surgeon to reproduce the surgical and pathological techniques used.
Radiotherapy
Radiotherapy details are sufficient to allow identical treatment and permit consistent reporting of dose.However the reasons for the use of a tumour volume boost in 9% of cases are not detailed. Since boosts would usually be applied in patients thought to be at risk of local recurrence (thus needing a higher dose), a confounding variable has been introduced.
Pathology
The method of pathological verification of excision margins is not detailed (frozen section or embedded specimens +/-inking), and the action of surgeons subsequently is also not described (number of re-excisions permitted to attain clear margins).Holland(25) has shown that multicentric lesions are uncommon, however for the purposes of this study, delineation of the pathological definition of singularity is required. Individual institutions provided the pathological diagnosis without central review, however the diagnosis of DCIS has already been shown to have a degree of inter-and intraobserver variation with respect to microinvasion and atypical ductal hyperplasia(32).A review panel of pathologists to maintain patient homogeneity and quality assurance of pathological processes is highly preferable in this study, since the appreciation of microinvasion is central to the raison d'etre of the study.
Such a panel increases a study's power(35).
Trial Analysis
Statistical Analysis
The statistical method used is the life-table estimate (Kaplan-Meier actuarial method)(36) to determine survival. The curves were compared with a two sided summary chi-square (log-rank) test(37). Other summary functions (average annual incidence rates, cumulative incidence rates, relative risks) were compared using the chi-square test.Statistical significance was determined by a p value of <0.05, and 95% confidence intervals were provided.The statistical analysis is suboptimal in the following aspects :
• given the null hypothesis that radiotherapy adds no advantage in terms of recurrence rates, event-free survival is not an adequate surrogate endpoint(38). Fortunately the other events are numerically evenly distributed; still the additional number of events will enhance attainment of statistical significance when the number of relevant endpoints is small.
• given the strong prior hypothesis that radiotherapy, as has been shown in early invasive carcinoma, would provide an advantage in 'endpoint' free survival, the use of a two sided test is another method of ensuring statistical significance. A one sided test is preferable for this study.
• The authors also tested for interactions with a univariate and multivariate proportional hazards analysis (method of Cox). This included stratification variables and treatment given. Unfortunately, important prognostic factors (size, comedo histology) have not been included, leaving the hazards analysis suspect.
• The more significant oversight revolves around the issue of prospective determination of study power (addressed above).
• annual evaluation of statistical significance is described. Frequent analyses is more likely to derive a false positive result. The details of data surveillance procedures should be provided along with methods to be utilised when statistical significance is attained. (7) Confounding Variables
Although the patient group contains a homogeneous and well defined population with DCIS, the inadequate stratification for prognostic factors will compromise subset analysis with later publications.The exclusion of the Montreal patients may introduce a confounder, but given the small numbers this is unlikely. A later analysis of this effect is expected.The use of a boost to the excision site indicates that prognostic factors are determining alteration in treatment, this will confound the results. Fortunately this occurrence was not common.
Trial Outcome Criteria for Evaluation Endpoints
The patients were observed at well-defined clinically-relevant intervals for endpoints that included :
• recurrence of ipsilateral breast cancer (including DCIS, invasive breast cancer)
• occurrence of contralateral breast cancer
The position and multicentricity of the recurrent lesions were noted and secondary treatment reported, however the rationale of secondary treatment was not detailed.In the analysis, the first event after treatment was used to define "event-free survival". This choice would produce optimistic results for two reasons :a. the study aimed to determine the effect of treatment in "preventing a second cancer in the ipsilateral breast", not event-free survival.b. in the randomised NSABP-B06 protocol, radiotherapy was shown to significantly increase the time to relapse without affecting overall survival.(38)The median follow-up time is only 42 months. Later analysis is likely to show an increased rate of local recurrence in both arms. The qualitative difference should remain and be more instructional.
Toxicity
There are no toxicity data reported, and this represents a major deficiency. Where the benefits of treatment are small, even slight toxicities may have significant impact on utility. In particular, where excisions have been small, the effects of radiotherapy on cosmesis should be meticulously detailed.
